Cytomegalovirus immunoglobulin

How it works

It provides passive immunity by supplying preformed antibodies that bind cytomegalovirus, supporting neutralisation and immune clearance during periods of risk.

Prescribing in practice

• Give by slow intravenous infusion with the rate titrated and the patient observed, as infusion-related and hypersensitivity reactions (including rare anaphylaxis, particularly in IgA-deficient recipients) can occur.
• As a blood-derived product it carries a theoretical risk of transmissible agents despite donor screening and viral-inactivation steps; batch records should be retained.
• It may transiently interfere with the response to live virus vaccines, which should be appropriately spaced.

Monitoring

Monitor infusion-site tolerance, vital signs and for hypersensitivity during and after administration.

Counselling the patient

• Tell the team at once if you feel flushed, wheezy, itchy or unwell during the infusion.
• This is a human plasma product given to help prevent CMV infection after transplant.

Evidence & guidelines

Use reflects product information and transplant guidance for CMV prophylaxis.